Fast-growing Danish biotech adopts Benchling
R&D Cloud for greater data accessibility, collaboration, and
compliance
SAN
FRANCISCO and ZURICH, April 23,
2024 /PRNewswire/ -- Today Benchling announced
that Zealand Pharma A/S, ("Zealand") a biotechnology company
focused on the discovery and development of peptide-based
medicines, has selected the Benchling R&D Cloud as its central
source of truth for scientific data, collaboration, and insights.
Teams across Zealand will use the Benchling R&D Cloud to
capture, analyze, and share stability data internally and with
their external contract manufacturing organization (CMO) partners,
in compliance with GxP.
"Our research progresses quickly, every action needs to be
traceable and verifiable. Scientists and partners can't be slowed
down by siloed systems or a lack of consistent data," said Ludo
Otterbein, Head of IT at Zealand Pharma. "Connecting the lab and
automating data capture and sharing through technology is a
critical priority. Benchling will provide Zealand with the digital
data foundation that helps us safely and confidently scale new use
cases and partners."
Zealand is a Nasdaq Copenhagen 25 (OMX C25) Index company with a
mission to change lives with next generation peptide medicines,
focusing on metabolic diseases such as obesity. The company works
across many CMOs and partners and requires real-time access to data
and secure, compliant information exchange. Zealand will deploy
Benchling as a GxP-compliant platform for their development teams,
including process development. With Benchling, Zealand scientists
will benefit from increased control and visibility of data, fewer
data transfer steps, and intuitive reporting and analytics,
including native integrations with tools like JMP.
"Zealand is a fast-growing biotech in a competitive space, and
they know that a strong digital strategy is key to success," said
Bob Burke, General Manager of
Benchling EMEA. "Benchling R&D Cloud gives Zealand the modern
technology to streamline and accelerate its development,
compliance, and partner needs. We look forward to building on this
collaboration and supporting Zealand's innovation."
Zealand will be a speaker at Benchling's upcoming Nordic Digital
Science & Innovation Day event, which brings together regional
leaders at the forefront of R&D innovation. The event takes
place on May 30, 2024 at Tivoli
Congress Center in Copenhagen, and
registration is now open.
About Benchling
Benchling creates the software that
powers the biotechnology industry, from cutting-edge start-ups to
over 20 of the 50 largest global biopharma. More than 200,000
scientists rely on the Benchling R&D Cloud as their central
source of truth for scientific data, analysis, and collaboration.
Benchling is on a mission to accelerate scientific progress through
advanced software that's purpose-built for biology. To learn more,
visit Benchling.com.
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the
discovery and development of peptide-based medicines. More than 10
drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. The company has
development partnerships with a number of pharma companies as well
as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the
U.S. For more information about Zealand's business and activities,
please visit www.zealandpharma.com.
View original
content:https://www.prnewswire.com/news-releases/zealand-pharma-partners-with-benchling-to-advance-rd-of-engineered-peptide-medicines-302123139.html
SOURCE Benchling